Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04024436 · ClinicalTrials.gov registry record · Phase 2
A Study of TAS-120 in Patients With Metastatic Breast Cancer
A Phase 2 study, sponsored by Taiho Oncology.
- Terminated
- Registry status
- Phase 2
- Development phase
- 64
- Enrollment target
NCT04024436 is a Phase 2 study that was terminated before completion, run by Taiho Oncology. The registered enrollment target is 64 participants.
The verdict
NCT04024436, a Phase 2 study, was terminated before completion, sponsored by Taiho Oncology.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 64 participants
- Enrollment target
Study Summary
The purpose of the trial is to evaluate a patient's response to a Fibroblast Growth Factor Receptor (FGFR) inhibitor, futibatinib (TAS-120), used either alone or in combination with the hormonal therapy, fulvestrant. This study will be conducted in patients with metastatic breast cancer who have specific Fibroblast Growth Factor Receptor gene abnormalities and who have previously received conventional therapies to treat their breast cancer, or who are not able to tolerate certain cancer therapies. This study will also evaluate the safety of taking futibatinib, or futibatinib and fulvestrant, by learning about the potential side effects.
Interventions
- DRUG Futibatinib
- DRUG Futibatinib plus Fulvestrant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2020-01-28 |
| Est. Completion | 2023-09-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04024436
The ClinicalTrials.gov registry entry for NCT04024436 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Taiho Oncology, which has 52 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Futibatinib is the first listed.
NCT04024436 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04024436 about?
NCT04024436 is a clinical study titled "A Study of TAS-120 in Patients With Metastatic Breast Cancer". The purpose of the trial is to evaluate a patient's response to a Fibroblast Growth Factor Receptor (FGFR) inhibitor, futibatinib (TAS-120), used either alone or in combination with the hormonal therapy, fulvestrant. This study will be conducted in patients with metastatic breast cancer who have spe...
What is the current status of trial NCT04024436?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 64 participants. The study started on 2020-01-28. Estimated completion is 2023-09-06.
What interventions are being tested in trial NCT04024436?
The interventions under investigation include: Futibatinib (DRUG), Futibatinib plus Fulvestrant (DRUG).
Who is sponsoring clinical trial NCT04024436?
This trial is sponsored by Taiho Oncology, which has 52 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.